Venture capital investments in biopharma companies are on track this year to beat out 2017 and every year prior, although the projected amount raised and the number completed appear to be shy of the record-breaking year of 2018. Read More
Barely a day goes by without news relating to cell and gene therapy companies being announced. Given the ongoing developments, it is not surprising that the sector continues to attract financing and business development remains robust, with biopharma companies ensuring that they secure a position in the space for themselves through partnering and acquisitions. Read More
